Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:vismodegib
|
| gptkbp:approvalYear |
2012-01-30
|
| gptkbp:ATCCode |
gptkb:L01XX43
|
| gptkbp:brand |
gptkb:Erivedge
|
| gptkbp:CASNumber |
879085-55-9
|
| gptkbp:chemicalFormula |
C19H14Cl2N2O3S
|
| gptkbp:genericName |
gptkb:vismodegib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Genentech
|
| gptkbp:mechanismOfAction |
Hedgehog pathway inhibitor
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue loss of appetite weight loss hair loss muscle spasms |
| gptkbp:usedFor |
basal cell carcinoma
|
| gptkbp:bfsParent |
gptkb:Roche
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Erivedge
|